NMS
Today Nerviano Medical Sciences , the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents.
Under the terms of the agreement, Nerviano Medical Sciences grants Merck an exclusive right to conduct joint research and to develop, manufacture and commercialize inhibitors of certain molecular targets in the area of DNA damage repair.
The collaboration between Nerviano Medical Sciences and Merck will initially focus on one target and shall encompass two stages. Nerviano Medical Sciences and Merck will first conduct research work in close collaboration with each other and Merck will subsequently further develop, manufacture and commercialize selected collaboration compounds.
Terms of the multiyear collaboration include an upfront fee in consideration of the rights and licenses granted by Nerviano Medical Sciences to Merck as well as partial funding of the costs incurred by Nerviano Medical Sciences for the conduct of the research program. As additional considerations, Merck shall pay research, development and commercial success milestones, as well as royalties on worldwide sales of products.
“This agreement between Merck and Nerviano Medical Sciences marks a new achievement in our collaboration strategy” - said Andrea Agazzi, Chairman of NMS Group . “We are very excited about the prospect of collaborating with Merck. We believe that by working together and applying our complementary world class research capabilities, we may be able to develop innovative and valuable products for the market.”
“We are thrilled at the prospect of joining forces with Merck in the discovery and development of innovative therapies in the field of defective DNA damage repair mechanisms, which both our teams view to be amongst the most important susceptibilities of cancer to be leveraged in the fight against this disease” - added Arturo Galvani, Head of Discovery Research at Nerviano Medical Sciences . “I believe that this partnership, which combines Nerviano’s expertise in the discovery and development of high-quality drug candidates with Merck’s scientific expertise as a global healthcare leader, is ideally configured for the task of delivering effective new therapies for the care of cancer patients.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20180601005366/en/
Contact:
Nerviano Medical Sciences
Chiara Lattuada
chiara.lattuada@nmsgroup.it
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Reply Optimizes Pusterla 1880’s Quotation Management with Oracle AI Capabilities, Reducing the Estimation Time by 90%29.4.2025 10:00:00 CEST | Press release
Technology Reply, the Reply Group company specialising in designing solutions based on Oracle technologies, today announced the development of an AI-based solution for managing the quotation process at Pusterla 1880. The implementation has reduced the time required to create new quotations to under five minutes and decreased the time needed to generate and validate cost estimates by 90%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429596543/en/ “Leveraging the AI capabilities offered by Oracle Cloud Infrastructure and Oracle Database 23ai, and supported by Technology Reply’s expertise, we have significantly streamlined our quotation process. This has enabled us to respond more quickly to customer requests while reducing the risk of errors in our decision-making,” said Luca Meana, President, Pusterla 1880. Pusterla 1880, a company with over 140 years of experience in luxury packaging production, faced increasing complex
CSG and NetLync Drive MNO and MVNO eSIM Transformation29.4.2025 09:30:00 CEST | Press release
Launch next-generation Entitlement SaaS platform that helps operators accelerate eSIM-only innovation and navigate the rapidly evolving telecom landscape With eSIM set to become the standard for all new phones this year,mobile network operators (MNOs) and mobile virtual network operators (MVNOs) face mounting pressure to modernize their entitlement infrastructure. To address this market need, CSG® (NASDAQ: CSGS) today announced a new partnership with leading entitlement server provider NetLync and launched CSG Entitlements-as-a-Service, powered by NetLync. This new SaaS platform gives operators the speed and agility they need to power seamless iOS and Android experiences in weeks, not months. It helps them stay competitive in an eSIM-only future and avoid the high costs of building and managing their own entitlement infrastructure. “The shift to eSIM-only devices drives a major change in the telecommunications industry that will redefine user experiences,” said Chad Dunavant, Chief Pro
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital29.4.2025 09:29:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo group’s recent press releases, lawsuits and other actions against SINOVAC and the Board, particularly those related to the Board’s decision to declare a cash dividend of US$55.00 per common share to SINOVAC shareholders. The Vivo group is now attempting to block the special dividend payments to you via lawsuits and by sending threatening letters and messages to the Company’s stock transfer agent and board members. It is particularly concerning that the Vivo group is trying to prevent all SINOVAC common shareholders (who hav
Suzano 2024 Annual Report on Form 20-F29.4.2025 09:29:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2024 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20250429838200/en/
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 09:00:00 CEST | Press release
Thanks to PUBG IP expansion, inZOI’s strong debut, and BGMI’s global growth, quarter-over-quarter sales are up 41.6%, while operating profit is up 112.2% KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom